City

Guangzhou (1)

Overall Status

Not yet recruiting (2)

Recruiting (1)

Phase

phase 2 (2)

phase 2/phase 3 (1)

Sponsor

Masonic Cancer Center, University of Minnesota (1)

Nanfang Hospital of Southern Medical University (1)

Tianjin Medical University Cancer Institute and Hospital (1)

Collaborator

Peking University People's Hospital (1)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)

Third Affiliated Hospital, Sun Yat-Sen University (1)

Zhujiang Hospital (1)

Intervention

aumolertinib,anlotinib (1)

busulfan (1)

busulfan (bu) (1)

cyclophosphamide (cy) (1)

decitabine (1)

fludarabine (1)

levetiracetam (1)

melphalan (1)

rituximab (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (3)

Study Type

Interventional (3)

tp53

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

Not yet recruiting

Aumolertinib
+4 more

Aumolertinib,Anlotinib

(no location specified)

Mar 8, 2023

Hematologic Malignancy, Acute Leukemia, Remission Trial (Fludarabine, Busulfan, Melphalan)

Not yet recruiting

Hematologic Malignancy
+21 more

Fludarabine
+4 more

(no location specified)

Feb 9, 2023

TP53, Myeloid Tumors, Conditioning Trial in Guangzhou (Decitabine, Busulfan (BU), Cyclophosphamide (CY))

Recruiting

TP53
+3 more

Decitabine
+2 more

Guangzhou, Guangdong, China

Department of Hematology,Nanfang Hospital, Southern Medical Univ

Oct 9, 2019